Skip to main content
Premium Trial:

Request an Annual Quote

Correction: Mar 11, 2005

Premium

RNAi News incorrectly reported last week that Cenix Bioscience has signed a deal with Schering expanding upon existing large-scale target screening projects. In fact,the arrangement is the companies’ first, and involves Cenix performing target validation for Schering, not target screening work.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.